Navigation Links
Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Date:11/21/2008

1 clinical trials and progressed further with the development of OXIGON(R), a small molecule intended for the treatment of AD and other disorders, including Parkinson's disease and other neurodegenerative diseases. Our development of OXIGON(R) was partially supported with federal funding from the National Institutes of Aging. We anticipate starting Phase 2 trials in AD patients next year.

3. Leverage our investment in our technology platforms:

  • We granted a non-exclusive, worldwide, royalty-bearing license to our ANTISENILIN(R) AD monoclonal antibody platform to Wyeth and Elan Pharmaceuticals. The license grants rights to Wyeth and Elan under Intellect's patents with respect to the development and sale of Bapineuzumab, a monoclonal antibody intended to treat AD. Wyeth and Elan are currently testing Bapineuzumab in several thousand Alzheimer's patients in a Phase 3 clinical trial. If successful, the drug could be launched early in 2012. Bapineuzumab has enormous sales potential as the first disease modifying drug in the field of AD and Intellect is entitled to a significant royalties on any future sales. The grant of this first license under our ANTISENILIN(R) patents was of great significance because it validated and established the value of our technology and of our business model that calls for broad licensing of our technology.

  • We recently granted an option to acquire a similar non-exclusive license to the ANTISENILIN(R) patents to another top tier pharmaceutical company that is developing its own monoclonal antibody for AD. The drug is currently being tested in humans. We are entitled to an upfront payment if and when this pharmaceutical company exercises the option in the first quarter of 2009 as well as patent milestones and royalties from sales. We are in discussions to grant additional licenses to oth
    '/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
10. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
11. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Orexigen ... it has received the Day 180 List of Outstanding ... Medicinal Products for Human Use (CHMP) for the NB32 ... / bupropion SR) is an investigational drug candidate being ... of the earlier Day 120 time point were adequately ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... Oct. 1 Maven Biotechnologies today announced that the ... Institute for Allergy and Infectious Disease (NIAID), part of ... TM imaging technology for label-free protein microarrays and ... Maven through the federal stimulus package initiative for Biomedical ...
... The Culex quinquefasciatus mosquito poses a significant ... elephantiasis-causing worms and encephalitis-inducing viruses. An international team of ... the SIB Swiss Institute of Bioinformatics sequenced its genome ... published in today,s issue of Science, describe results from ...
... 1 Vet-Stem, Inc. announced that Dr. Robert Harman, ... entitled "Stem Cell Therapy: Mechanisms of Action" at the ... Surgeons (ACVS) in Seattle, WA, October 21, 2010.   ... http://www.newscom.com/cgi-bin/prnh/20060425/VETSTEMLOGO ) Dr. Harman has presented ...
Cached Biology Technology:Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics 2Major disease-vector mosquito reveals the secrets of its immune system 2Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2
(Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
(Date:7/30/2014)... associate professor Andrew S. Mount, performed cutting-edge research on ... novel anti-fouling paint for ships and boats and also ... team,s findings, published in Nature Communications ... attaches to a wide variety of surfaces using highly ... underwater heavy-duty adhesive. , "In previous research, we were ...
(Date:7/30/2014)... pests, shrinking ranges and a changing climate threaten ... important plants, and so conservationists establish seed collections ... gardens in hopes of preserving some genetic diversity., ... by simple models that offer a one-size-fits-all approach ... recommending saving 50 seed samples regardless of species, ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Saving seeds the right way can save the world's plants 2
... researchers are part of a nationwide team preparing to open ... genome of the single living sister species to all other ... a large shrub found only on the South Pacific island ... diversified over time and provide insight into the key processes ...
... The Ohio State University and Ohio Supercomputer Center ... develop a computer tool that researchers, government leaders and ... in energy-related technology, policy and pricing. Researchers will ... for Energy Pricing and Policy (ICS-EPP), which models the ...
... PHILADELPHIA The American Association for Cancer Research congratulates 12 ... Medicine. They are among the 65 new members and five ... the fields of health and medicine, the award recognizes individuals ... in the fields of health and medicine. "This ...
Cached Biology News:UF to help sequence genome of flowering plants' ancient living relative 2UF to help sequence genome of flowering plants' ancient living relative 3NSF grant to study national energy policy and technology impacts 2The AACR congratulates its members elected to the Institute of Medicine 2
... thermal cycler is a compact instrument for gene ... tubes, 12 x 0.5 ml tubes, or a ... a thumbwheel to adjust height and pressure to ... heat pumps provide excellent thermal performance, and the ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
... with SR-101 Labeled Substrates (red fluorescence; ... measure serine protease activation • No ... FLISP Kits utilize cell-permeable, fluorescently labeled ... measure chymotrypsin-like activity in whole living ...
... MitoPT kit is used in conjunction with your ... and induce apoptosis according to your existing procedure ... a negative control). Once you have induced apoptosis ... to each population and incubate the cells for ...
Biology Products: